Name (Synonyms) | Correlation | |
---|---|---|
D001167 | Arteritis NIH | 0.71 |
D011111 | Polymyalgia Rheumatica NIH | 0.58 |
D013700 | Giant Cell Arteritis NIH | 0.58 |
D003095 | Collagen Diseases NIH | 0.50 |
D015535 | Arthritis, Psoriatic NIH | 0.50 |
D012216 | Rheumatic Diseases NIH | 0.45 |
D008180 | Lupus Erythematosus, Systemic NIH | 0.41 |
D001168 | Arthritis NIH | 0.29 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0012089 | Arteritis HPO | 0.71 |
HP:0002725 | Systemic lupus erythematosus HPO | 0.41 |
HP:0001369 | Arthritis HPO | 0.29 |
There is one clinical trial.
The trial is a prospective, observational study aiming to identify risk factors for serious COVID-19 infection by evaluating clinical measures and biomarkers of inflammation in patients with inflammatory rheumatic disease hospitalized with COVID-19 compared with control groups.
Description: The objective is to examine whether increased disease activity leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease
Measure: Disease activity Time: Last registration of disease activity in the medical journal before admission/inclusionDescription: Examine whether immune modulating treatments protect or leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease.
Measure: Immune modulating treatments Time: Current immune modulating treatments at admission/inclusionDescription: Identify prognostic biomarkers by comparing serology of patients with inflammatory rheumatic disease hospitalized with COVID-19 and comparing them with the two control groups
Measure: Biomarkers Time: Blood sample 1 is taken 0-3 days after inclusion and blood sample 2 is taken 2-6 weeks after blood sample 1